(9Z,12Z)-N-methoxy-N-methyloctadeca-9,12-dienamide | 577973-81-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (9Z,12Z)-N-methoxy-N-methyloctadeca-9,12-dienamide
• 英文别名: (9Z,12Z)-N-Methoxy-N-methyl-9,12-octadecadienamide
• CAS: 577973-81-0
• 化学式: C₂₀H₃₇NO₂
• 分子量: 323.519
• InChiKey: DTXISTLEGHJAOL-MURFETPASA-N

物化性质

• 沸点：
  409.4±48.0 °C(Predicted)
• 密度：
  0.907±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  23
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (9Z,12Z)-N-methoxy-N-methyloctadeca-9,12-dienamide 在 四丁基氟化铵 、 叔丁基锂 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 0.08h， 生成 (12Z,15Z)-1-Hydroxy-henicosa-12,15-dien-4-one
  参考文献：
  名称：

  Hemisynthesis and preliminary evaluation of novel endocannabinoid analogues

  摘要：

  Three new endocannabinoid analogues in which amide moiety was replaced either by oxomethylene group or ester moiety with simultaneous substitution of both alpha-hydrogens with methyl groups were synthesized and their abilities to interact with CB1-receptor and FAAH were investigated. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00348-2
• 作为产物：
  描述：

  (Z,Z)-9,12-十八烷二烯酸二聚物 在 N-甲基吗啉 作用下， 以 乙腈 为溶剂， 生成 (9Z,12Z)-N-methoxy-N-methyloctadeca-9,12-dienamide
  参考文献：
  名称：

  Hemisynthesis and preliminary evaluation of novel endocannabinoid analogues

  摘要：

  Three new endocannabinoid analogues in which amide moiety was replaced either by oxomethylene group or ester moiety with simultaneous substitution of both alpha-hydrogens with methyl groups were synthesized and their abilities to interact with CB1-receptor and FAAH were investigated. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00348-2

文献信息

• Cationic lipid
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US10731159B2

  公开（公告）日：2020-08-04

  The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.

  本发明提供了一种由式（Ia）表示的化合物，作为一种新型阳离子脂质，可形成脂质颗粒，还提供了一种包含该化合物的脂质颗粒。本发明进一步提供了一种含有该脂质颗粒的核酸脂质颗粒，以及一种含有该核酸脂质颗粒作为活性成分的药物组合物。
• NOVEL LIPID
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP3020701B1

  公开（公告）日：2018-09-26
• CATIONIC LIPID
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US20180051285A1

  公开（公告）日：2018-02-22

  The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the nucleic acid lipid particle as an active ingredient.
• US9803199B2
  申请人：——

  公开号：US9803199B2

  公开（公告）日：2017-10-31